Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Outlook Therapeutics (OTLK) is back in focus after the FDA accepted its resubmitted Biologics License Application for ONS-5010/Lytenava as a Class 1 review, without requiring additional clinical trials.

See our latest analysis for Outlook Therapeutics.

That regulatory update has come alongside sharp price moves, with Outlook Therapeutics posting a very large 30 day share price return of about 409% and a 90 day share price return of 193%. However, the 1 year total shareholder return is down 34%, suggesting momentum has picked up recently against a weaker long term record.

If this kind…